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ABSTRACT
An inflammatory and cytotoxic CD4CD28– T cell sub-
set infiltrates atherosclerotic plaques and is implicated
in plaque rupture and myocardial infarctions. This
pathologic subset develops with replicative stress and
is found in patients with chronic inflammatory diseases
such as RA as well as with aging. CD4CD28– cells
overexpress genes normally suppressed by DNA meth-
ylation in CD4CD28 T cells, such as KIR, perforin,
and CD70. How this subset overexpresses methyla-
tion-sensitive genes is unknown. DNA methylation
patterns are maintained in proliferating cells by
Dnmts, which are up-regulated during mitosis by the
ERK and JNK signaling pathways. We hypothesized
that defects in these signaling pathways contribute to
altered gene expression in human CD4CD28– cells
through effects on DNA methylation. We report that
signaling through the ERK and JNK pathways is de-
creased in CD4CD28– relative to CD4CD28 cells
from the same individuals and that ERK and JNK
pathway inhibition decreases Dnmt1 and -3a levels,
which in turn, causes demethylation and overexpres-
sion of the TNFSF7 (CD70) gene. We also report that
CD4CD28– T cells overexpress PP5, a stress-in-
duced inhibitor of the ERK and JNK signaling path-
ways that may contribute to the signaling defects. We
conclude that decreased ERK and JNK signaling in
the CD4CD28– subset, arising with replicative
stress, can lead to the overexpression of normally
suppressed genes through effects on Dnmts and
consequently, chromatin structure. J. Leukoc. Biol.
87: 137–145; 2010.
Introduction
CD4CD28– T cells are a heterogeneous subset found in el-
derly people as well as in patients with chronic inflammatory
diseases such as RA [1, 2]. This subset develops with repeated
mitogenic stimulation that results in damage to DNA and cel-
lular components, referred to as replicative stress, and is char-
acterized by decreased replicative potential, low telomerase
levels, and shortened telomeres similar to other “senescent”
cells [2, 3]. The CD4CD28– subset expands in patients with
acute coronary syndromes (unstable angina and myocardial
infarctions) and is found in ruptured atherosclerotic plaques
of people with fatal myocardial infarctions. These T cells se-
crete large amounts of IFN-, are cytotoxic to endothelial cells
[1], and are implicated in atherosclerotic plaque development
and rupture [4, 5].
CD4CD28– T cells also overexpress genes such as KIR,
perforin, and CD70, which contribute to the IFN- and cyto-
toxic responses [1, 6]. These genes are normally suppressed in
CD4 T cells by DNA methylation [7–9], a covalent modifica-
tion promoting a transcriptionally repressive chromatin struc-
ture [10]. Our group reported that Dnmt1 and Dnmt3a are
decreased in this subset, causing demethylation and overex-
pression of these genes [8]. How Dnmt levels are decreased in
this subset is unknown. Dnmt1 is up-regulated following mito-
genic stimulation by signals transmitted through the ERK and
JNK pathways [11]. Dnmt3a is similarly up-regulated in part by
signaling through the ERK pathway [12], although the role of
JNK signaling in Dnmt3a regulation is unknown.
T cell signaling abnormalities develop with age [13]. We hy-
pothesized that ERK and/or JNK signaling may be decreased in
the CD4CD28– subset, leading to decreased Dnmt levels and
demethylation of methylation-sensitive genes. We therefore com-
pared ERK and JNK signaling pathways in CD4CD28 and
CD4CD28– T cells generated by in vitro proliferative stress, RA,
and aging and determined whether decreased ERK and/or JNK
signaling could cause demethylation and overexpression of meth-
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ylation-sensitive T cell genes. We also sought mechanisms contrib-
uting to the decreased signaling.
MATERIALS AND METHODS
Subjects
Subjects with RA (n17, 5514 years old, meansd) met revised criteria
for RA [14] and were recruited from the University of Michigan Arthritis
Clinics (Ann Arbor, MI, USA). Healthy subjects 60 years of age (n15,
3816 years old, meansd) were obtained by advertising. Healthy subjects
60 years of age (n10, 727 years old) with osteoarthritis but without
known chronic inflammatory diseases or other significant illnesses were
similarly recruited from the University of Michigan Arthritis Clinics and the
Human Subjects Core of the University of Michigan Claude D. Pepper
Older Americans Independence Center. We and others [8] have found no
relationship between medications received and gene expression alterations
in RA subjects. This protocol was approved by the University of Michigan
Institutional Review Board.
CD4CD28– T cell quantitation, isolation, and
culture
PBMC were isolated from healthy donors and RA patients by Ficoll-
Hypaque density centrifugation, and CD4 and CD28 expression was mea-
sured by multi-color flow cytometry as described [15]. Total T cells, CD4
T cells, or the CD4CD28 and CD4CD28– subsets were purified using
magnetic beads (Miltenyi Biotec, Auburn, CA, USA) and previously pub-
lished protocols; purity is typically 95–98% by flow cytometry [8]. Where
indicated, PBMC were stimulated with 1 g/ml PHA and cultured in com-
plete media (RPMI 1640/10% FBS supplemented with penicillin and strep-
tomycin) also as described [15]. The signaling inhibitors PD98059 (Pro-
mega, Madison, WI, USA; 12.5 M, 25 M, 50 M), U0126 (Promega; 10
M, 20 M, 40 M), and/or SP600125 (Biosource, Carlsbad, CA, USA; 5
M, 10 M, 20 M) were added where indicated. CD4CD28– T cells
were generated in vitro by stimulating PBMC from healthy, younger donors
with PHA and then culturing bead-purified CD4 cells in complete media,
supplemented with 10 ng/ml rIL-2 (PeproTech, Rocky Hill, NJ, USA) and
restimulating weekly with 106 irradiated (2500R) allogeneic PBMC/2.5 
106-cultured CD4 T cells [16]. Fifty-two percent to 86% of the CD4 cells
were typically CD28– by Weeks 4–6.
siRNA “knockdown” and Dnmt levels
Purified T cells from healthy donors were transfected with 3 g control or
MEK- or JNK-specific siRNA (Dharmacon, Lafayette, CO, USA) using Amaxa
(Walkersville, MD, USA) nucleofection, according to the manufacturer’s in-
structions. For double-knockdowns, 3 g each siRNA was used. The target se-
quence for the down-regulation of both MEK isoforms was 5-CAGAA-
GAAGCTGGAGGAGC-3, found in MEK1 mRNA and MEK2 mRNA. Similarly,
the target sequence for the down-regulation of both JNK isoforms was 5-
GAAAGAATGTCCTACCTTC-3, found in JNK1 mRNA and JNK2 mRNA.
BLAST searches were performed to verify the specificity of these sequences.
Six hours after transfection, the medium was changed, as per the manufactur-
er’s instructions. Forty-eight hours following transfection, an aliquot of the
cells was stimulated with PHA and Dnmt3a measured 6 h later, and Dnmt1
was measured 24 h later (vide infra) [12]. T cells express little Dnmt3b and so,
were not studied [12]. At 72 h, the CD4 cells were stimulated with PMA for
15 min and then purified, lysed, and protein isolated to verify suppression of
MEK and JNK by Western blotting with MEK1/2 and JNK1/2 antibodies (Cell
Signaling Technology, Beverly, MA, USA), performed as described [17]. RNA
and DNA were also purified from the CD4 cells at 72 h, as described for
CD70 mRNA and DNA methylation analyses [18].
Flow cytometric signaling assays
For ERK and JNK signaling, PBMC were stained with FITC-labeled anti-CD28
(BD PharMingen, San Jose, CA, USA) and then cultured alone or with 50
ng/ml PMA and 50 ng/ml ionomycin for 15 min at 37°C. Treated and un-
treated cells were then fixed in prewarmed (37°C) Cytofix buffer (BD Bio-
science, San Jose, CA, USA) for 10 min and then permeabilized in Phosflow
Perm Buffer III (BD Bioscience) for 30 min on ice. The permeabilized cells
were washed twice in PBS/3% FBS/0.1% sodium azide and then stained
with PE-labeled anti-pERK1/2 (T202/Y204), purified rabbit anti-JNK
(pT183/pY185), and PE-Cy5-labeled anti-CD4, respectively. For the de-
tection of pJNK, the cells were reacted with PE-conjugated F(ab)2 don-
key anti-rabbit IgG. Isotype-matched control antibodies were used for
surface and intracellular controls. All antibodies were obtained from BD
PharMingen. The stained cells were then analyzed on a FACSCalibur
cytometer (BD Bioscience) equipped with emission filters for FITC, PE,
and Cy5-PE. Fold change was calculated by dividing the MFI of MFI stim
by that of MFI unstim, i.e., MFI stim/MFI unstim. Serine/threonine PP5
was similarly quantitated using a 1/50 dilution of rabbit anti-PP5 anti-
body (Cell Signaling Technology). Isotype-matched control antibodies
(BD PharMingen) were used for surface and intracellular controls [19].
Dnmt1, Dnmt3a, ERK, JNK, and PP5 immunoblotting
Where indicated, T cells were stimulated for 15 min with 50 ng/ml PMA 
50 ng/ml ionomycin and lysed, and then total and pERK and pJNK were
measured by immunoblotting as described [17]. PP5 was quantitated using
antibodies from Cell Signaling Technology.
Dnmt1, Dnmt3a, and CD70 quantitation
PBMC from healthy subjects were stimulated with PHA and treated with the
MEK inhibitors PD98058 or U0126 and/or the JNK inhibitor SP600125, and
then Dnmt3a mRNA and protein were measured 6 h later, and Dnmt1 mRNA
and protein were measured 24 h later using protocols published previously
[12]. Dnmt1 transcript levels are cell cycle-linked and so, were measured rela-
tive to histone H4, a similarly cell cycle-linked transcript, 24 h following stimu-
lation, and Dnmt3a mRNA levels are maximal at 6 h following stimulation and
so, were measured relative to the housekeeping gene -actin [12]. CD70 tran-
scripts were measured relative to -actin 72 h following treatment with inhibi-
tors also using protocols published previously [18].
Figure 1. Percent CD4CD28– T cells in younger and older, healthy
subjects and in RA patients. PBMC from 15 healthy subjects, 38  16
(meansd) years of age (controls 60); 10 healthy subjects, 72  7
years of age (controls 60); and 17 RA patients, 55  14 years of age,
were stained with anti-CD4-FITC and anti-CD28-PE, and then the per-
cent CD4CD28– T cells was determined using two-color flow cytom-
etry. P values refer to the difference in percent CD4CD28– relative
to the young cohort.
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Bisulfite sequencing
CD70 promoter methylation was determined by bisulfite sequencing as de-
scribed previously [18], cloning, and sequencing 10 fragments/sample.
Statistical analysis
Statistical analyses were performed using Student’s t-test or ANOVA as ap-
propriate and Systat (Evanston, IL, USA) software.
RESULTS
CD4CD28– T cells increase in RA and in older,
healthy individuals
Figure 1 shows the percent of CD4CD28– T cells relative to
total CD4 T cells in the control and RA cohorts used in this
study and confirms that healthy older people [age 60, 727
(meansd) years of age, n10] and patients with RA (5514
years, n17) have a significantly greater percentage of
CD4CD28– T cells than younger (age 60, 3816 years,
n15) individuals as reported by others [1]. No significant
difference in the percent CD4CD28– was seen between the
healthy, older cohort and the RA cohort.
ERK and JNK signaling is decreased in CD4CD28–
T cells
Initial studies compared ERK and JNK signaling pathways in
CD4CD28 – T cells generated in vitro using repeated stim-
ulation to cause replicative stress. PBMC from five healthy
donors ages 23– 62 years (4516, meansd) were stimu-
lated with PHA, and then CD4 T cells were purified and
maintained as long-term lines by weekly restimulation with
Figure 2. ERK and JNK activation in CD4CD28 and CD4CD28 –
T cells. (A) Mean  sem of six experiments similar to those shown
in Supplemental Figure 1 using immunoblotting to compare phos-
phorylated to total ERK and JNK in PMA-stimulated CD4CD28 T
cells (open bars) and CD4CD28 – T cells (solid bars), generated by
repeated stimulation in vitro. (B) Unstimulated (light lines) and
PMA  ionomycin-stimulated (dark lines) T cells from a patient with
RA were stained with PE-Cy5-labeled anti-CD4, FITC-anti-CD28 –, and
anti-pERK-PE or anti-pJNK-PE and then analyzed by flow cytometry
as described in Materials and Methods. The shaded histograms rep-
resent isotype controls for the antibodies to the signaling molecules.
The upper left panel shows pERK in CD4CD28 cells, the lower
left pERK in CD4CD28 – cells, the upper right pJNK in CD4
CD28 cells, and the lower right pJNK in CD4CD28 – cells.
(C) Bar graph showing the pERK MFI in CD4CD28 cells (open
bars) and pERK MFI in CD4CD28 – cells (solid bars) in T cells
from nine healthy controls age 60, 11 RA patients, and six controls
age 60. (D) Bar graphs similarly showing pJNK MFI in
CD4CD28 and CD4CD28 – T cells from the same subjects.
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irradiated, allogeneic PBMC and media supplemented with
IL-2. After 4–6 weeks, the cells were fractionated into CD28
and CD28 – subsets, stimulated with PMA  ionomycin, and
cytoplasmic pERK and pJNK measured. At the time of har-
vest, 51  11% of the cells were CD4CD28 – (meanSEM,
n5). Supplemental Figure 1 shows representative immuno-
blots comparing total and pERK and pJNK in CD4CD28
and CD4CD28 – T cells. pERK and pJNK are decreased in
the CD28 – subset. Figure 2A shows the mean  sem of six
similar experiments comparing pERK and pJNK in CD4
CD28 and CD4CD28 – T cells. pERK and pJNK are im-
paired significantly in the CD4CD28 – subset.
We then compared pERK and pJNK in CD4CD28 and
CD4CD28– T cells isolated from the peripheral blood of
younger and older subjects without chronic inflammatory con-
ditions and in patients with RA. The number of CD4CD28–
cells in peripheral blood is limiting (Fig. 1), so flow cytometric
approaches described and validated by others [19] were used
to compare pERK and pJNK levels in CD4CD28 and
CD4CD28– cells. Figure 2B shows representative histograms
of pERK and pJNK staining in unstimulated and stimulated
(PMAionomycin) CD4CD28 and CD4CD28– cells from
a 53-year-old woman with RA. There is less pERK and pJNK in
the CD28– subset. Figure 2C shows the mean  sem of similar
pERK staining in stimulated CD4CD28 and CD4CD28– T
cells from nine younger, healthy people (age 60 years,
3916 years old, meansd), six older, healthy subjects (age
60, 774 years old), and 11 RA patients (5416 years old),
and Figure 2D shows pJNK staining in stimulated
CD4CD28 and CD4CD28– T cells from the same sub-
jects. pERK and pJNK were decreased by approximately the
same degree in CD4CD28– T cells from all three groups.
Inhibiting ERK and/or JNK signaling decreases
Dnmt1 and Dnmt3a expression
We next determined the effect of inhibiting ERK and JNK sig-
naling, alone and in combination, on total T cell Dnmt1 and
Dnmt3a levels. PBMC from young (18–30 years old), healthy
controls were stimulated with PHA and treated with graded
concentrations of the MEK inhibitors PD98059 or U0126
and/or the JNK inhibitor SP600125, and then Dnmt3a mRNA
and protein were measured in T cells 6 h later, and Dnmt1
mRNA and protein were measured after 24 h [12]. Figure 3A
shows the effects of the MEK inhibitor PD98059 and the JNK
inhibitor SP600125 alone and in combination on Dnmt1
mRNA. PD98059 and SP600125 together decreased Dnmt1
levels to a slightly greater extent than PD98059 alone (P0.03
by t-test; PD98059 50 M alone vs. PD98059 50 MSP600125
20 M). Figure 3B shows a similar experiment using the MEK
inhibitor U0126 and SP600125, alone and in combination on
Dnmt1. Each inhibitor alone suppressed T cell Dnmt1 tran-
scripts, and again, there was a small additive effect when com-
bined (P0.02). Similar effects on Dnmt3a mRNA levels were
observed when MEK and JNK pathways were inhibited.
PD98059 and SP600125 (Fig. 3C) and U0126 and SP600125
(Fig. 3D) had effects on Dnmt3a transcripts resembling those
observed on Dnmt1.
We then compared the effects of the MEK and JNK inhibi-
tors in purified CD4 T cells. Figure 3E shows suppressive ef-
fects of U0126 and SP600125 alone and in combination on
Dnmt1 mRNA (P0.007; U0126 40 M vs. U0126 40
MSP600125 20 M), and Figure 3F shows similar effects on
Dnmt3a (P0.05; U0126 40 M vs. U0126 40 MSP600125
20 M). The results again are additive and resemble those
seen in unfractionated T cells.
Figure 3G shows a representative immunoblot confirming a
decrease in Dnmt1 at the protein level caused by the MEK in-
hibitors, the JNK inhibitor, or both, and Figure 3H similarly
shows an immunoblot confirming a decrease in Dnmt3a pro-
tein caused by the MEK inhibitors, the JNK inhibitor, or both.
Together, these results indicate that defects in the ERK signal-
ing pathway, the JNK signaling pathway, or both can decrease
Dnmt1 and Dnmt3a levels.
Inhibiting ERK and/or JNK signaling causes TNFSF7
demethylation and overexpression
We reported previously that siRNA knockdowns of Dnmt1 and
Dnmt3a were additive in causing demethylation and overex-
4
Figure 3. Effect of ERK and JNK pathway inhibitors on T cell Dnmt1 and Dnmt3a. (A) PBMC from young, healthy controls were stimulated with
PHA and treated with graded concentrations of the MEK inhibitor PD98059 (12.5 M, 25 M, or 50 M), the JNK inhibitor SP600125 (5 M, 10
M, or 20 M), or both, and then T cells were isolated and Dnmt1 transcripts measured relative to histone H4 24 h later. Results represent the
mean  sem of four independent experiments. (B) PBMC from healthy controls were similarly stimulated and treated with the MEK inhibitor
U0126 (10 M, 20 M, 40 M), SP600125 (5 M, 10 M, or 20 M), or both, and T cell Dnmt1 mRNA was measured as in A. Results again rep-
resent the mean  sem of four independent experiments. (C) PBMC from young, healthy controls were stimulated with PHA and treated with
graded concentrations of PD98059, SP600125, or both as in A, and then T cells were purified, and Dnmt3a transcripts were measured relative to
actin 6 h later. Results represent the mean  sem of four independent experiments. (D) PBMC from healthy controls were similarly stimulated
and treated with U0126, SP600125, or both as in B, and T cell Dnmt3a mRNA was measured as in C. Results again represent the mean  sem of
four independent experiments. (E) PBMC from young, healthy controls were stimulated with PHA and treated with graded concentrations of the
MEK inhibitor U0126 (10 M, 20 M, or 40 M), the JNK inhibitor SP600125 (5 M, 10 M, or 20 M), or both as in A, and then CD4 T cells
were isolated and Dnmt1 transcripts measured relative to histone H4 24 h later. Results represent the mean  sem of three independent experi-
ments. (F) PBMC from healthy controls were similarly stimulated and treated with U0126, SP600125, or both, and then CD4 T cell Dnmt3a
mRNA was measured as in B. Results again represent the mean  sem of three independent experiments. (G) PBMC were stimulated with PHA,
treated with PD98059 (25 and 50 M; PD25 and PD50, respectively), U0126 (20 and 40 M; U20 and U40, respectively), SP600125 (10 and 20
M; SP10 and SP20, respectively), or 50 M PD98059  20 M SP600125 (PD50 SP20) or 40 M U0126  20 M SP600125 (U40 SP20) as in A
and B, and then T cell Dnmt1 and actin were measured by immunoblotting. (H) PBMC were stimulated with PHA and treated with U0126,
SP600125, or U0126  SP600125 as in G, and then T cell Dnmt3a and actin were measured by immunoblotting as in G. MEKi, MEK inhibitor;
JNKi, JNK inhibitor; Con, control.
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pression of KIR, perforin 1, and TNFSF7 (CD70), normally
suppressed by DNA methylation in CD4 T cells [8]. We
therefore determined if decreasing signaling through the ERK
and JNK pathways had similar effects on T cell DNA methyl-
ation and gene expression. CD70 is a B cell costimulatory mol-
ecule regulated in part by methylation of a sequence flanking
the core promoter. Inhibiting T cell DNA methylation demeth-
ylates this sequence and increases CD70 expression, and meth-
ylation of this sequence in reporter constructs suppresses pro-
moter function [18]. Figure 4A shows that U0126 and
SP600125, used at the maximum concentrations shown in Fig-
ure 3, increased CD70 transcripts in CD4 T cells and that
their effects were additive. Supplemental Figure 2, A–D, shows
the effects of treatment with U0126, SP600125, and U0126 
SP600125 on the methylation of each CG pair in the CD70
promoter using bisulfite sequencing performed on CD4 T
cells from four donors. Figure 4B depicts the average methyl-
ation across this region, calculated from the results shown in
Supplemental Figure 2. The region shown previously to de-
methylate in drug-treated T cells and in human lupus T cells
[18] also demethylated in T cells treated with MEK and JNK
inhibitors, again, in an additive manner (P0.002 overall by
ANOVA).
These results were confirmed using siRNA knockdowns to
decrease MEK and JNK. Supplemental Figure 3 shows total
and pMEK, pERK, and pJNK protein in PMA-stimulated T
cells transfected with a MEK siRNA, a JNK siRNA, or both.
The MEK siRNA decreased levels of total MEK and similarly
decreased levels of pMEK and pERK, and JNK siRNA de-
creased total and pJNK. Figure 5A shows densitometric analysis
of immunoblots, confirming the effects on MEK protein, and
Figure 5B similarly shows densitometric analysis of immuno-
blots, confirming effects on JNK. The siRNAs demonstrated
specificity and efficacy. Figure 5C shows that the MEK and
JNK siRNAs decreased Dnmt1 mRNA and that their effects are
modestly additive, and Figure 5D shows similar results on
Dnmt3a transcripts (P0.01 for all).
Figure 6A shows that the MEK and JNK siRNAs also in-
creased CD70 expression and that their effects were additive,
similar to the results seen with the pharmacologic inhibitors
shown in Figure 4. Supplemental Figure 4, A–D, compares the
effects of transfection with the MEK and JNK siRNA, alone
and in combination on CD70 promoter methylation using
bisulfite sequencing as in Figure 4, performed on CD4 T
cells from three to four donors, and Figure 6B shows the aver-
age methylation across this region for the control and trans-
fected cells. The MEK and JNK siRNAs similarly demethylated
the CD70 promoter, and their effects were again additive. To-
gether, these experiments demonstrate that inhibiting the
ERK and JNK signaling pathways, with pharmacologic inhibi-
tors or siRNA, decreases Dnmt1 and Dnmt3a expression and
causes demethylation and overexpression of CD70.
Mechanisms decreasing ERK and JNK signaling in
CD28– T cells
We next investigated mechanisms contributing to decreased
signaling in the ERK and JNK pathways in CD4CD28– T
cells. Oxidative stress plays a major role in cellular senescence
[20]. PP5 is a regulator of stress-induced signaling pathways,
including oxidative stress, and inactivates ASK1, preventing
JNK activation [21, 22]. PP5 also inactivates the ERK signaling
pathway by dephosphorylating Raf-1 [23]. We therefore com-
pared PP5 levels in CD4CD28 and CD4CD28– T cells
generated by repeated stimulation. Figure 7A shows PP5 pro-
tein in CD4CD28 and CD4CD28– T cells from four
young, healthy donors. PP5 expression was increased in the
CD28– subset. Figure 7B shows the densitometric analyses of
PP5 relative to -actin in similar immunoblots performed on
CD4CD28 and CD4CD28– T cells from eight young, healthy
controls. PP5 levels were significantly (P0.01) higher in CD28– T
cells. Figure 7C shows representative flow cytometric histograms of
PP5 levels in CD4CD28 and CD4CD28–, respectively, in T
cells from a healthy control without chronic inflammatory dis-
Figure 4. Effect of ERK and JNK pathway inhibitors on CD4 T cell
TNFSF7 (CD70) expression and methylation. (A) PBMC were stimu-
lated with PHA and then left untreated (Control) or treated with 40
M U0126, 20 M SP600125, or both (USP), and 72 h later, CD70
mRNA was measured in purified CD4 T cells. Results represent the
mean  sem of three independent experiments. (B) The overall meth-
ylation of the TNFSF7 promoter was determined for each experimen-
tal condition for each subject, and then the mean of the results for
the four subjects was determined. The results are presented as the
mean  sem of the four determinations/experimental condition
and significance determined relative to untreated cells using Stu-
dent’s t-test.
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ease. Again, the CD28– subset had higher PP5 levels. Figure
7D compares PP5 levels in CD4CD28 and CD4CD28– T
cells in five healthy subjects age 60 years (22–59, 3719
years, meansd) 4 subjects 60 (61–74, 647 years) without
known chronic inflammatory disease, and six RA patients (45–
72, 559 years). Again, CD28– T cells have higher PP5 levels
in all three groups. This suggests that the signaling regulator
PP5 contributes to decreased signaling through the ERK and
JNK pathways in the CD4CD28– subset as in other cells sub-
jected to oxidative stress [21–23].
DISCUSSION
We and others [7, 18, 24–26] reported that some of the genes
overexpressed in CD4CD28– T cells, such as CD11a, per-
forin, CD70, IFN-, and the KIR gene family, are suppressed
normally in T cells by DNA methylation and that inhibiting
replication of DNA methylation patterns during mitosis is suffi-
cient to increase their expression. Our group also reported
that the CD70, perforin, and KIR2DL4 promoters are demeth-
ylated in CD4CD28– T cells, that Dnmt1 and Dnmt3a levels
Figure 5. Effects of T cell MEK and/or JNK RNA interference knockdowns on Dnmt lev-
els. (A) Densitometric analysis of two experiments similar to those shown in Supplemen-
tal Figure 3 comparing control siRNA, MEK siRNA, JNK siRNA, or MEK  JNK siRNA on
total MEK. Results represent the mean  sd of the two experiments. (B) Densitometric
analysis of two experiments similar to those shown in A comparing MEK siRNA, JNK
siRNA, or both on total JNK. Results again represent the mean  sd of the two experi-
ments. (C) T cells from healthy donors were transfected with control siRNA, MEK siRNA,
JNK siRNA, or MEK  JNK siRNA and then 48 h later, stimulated with PHA as in Figure
3. Dnmt1 mRNA was measured 24 h later as in Figure 3. Results represent the mean 
sem of three independent experiments. (D) T cells were similarly transfected with control
siRNA, MEK siRNA, JNK siRNA, or MEK  JNK siRNA as in Supplemental Figure 3 and
then 48 h later, stimulated with PHA and Dnmt3a transcripts, measured 6 h later as in
Figure 3. Results again represent the mean  sem of three independent experiments.
*, P  0.01.
Figure 6. Effects of MEK and/or JNK siRNA on CD4 T cell TNFSF7 (CD70) expression and methylation. (A) T cells from three young, healthy
controls were transfected with control siRNA, MEK siRNA, JNK siRNA, or MEK  JNK siRNA as in Figure 5, stimulated 48 h later with PHA, and
24 h later, CD70 mRNA was measured as described in Figure 4. Results represent the mean  sem of the three independent experiments. *, P 
0.003. (B) The overall methylation of the TNFSF7 promoter was determined for each experimental condition for each subject, and then the mean
of the results for the subjects was determined as in Figure 4. The results are presented as the mean  sem of three to four determinations/experi-
mental condition.
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are decreased in this subset, and that siRNA knockdown of
Dnmt1, but not Dnmt3a, in CD4CD28 T cells caused simi-
lar demethylation and overexpression of KIR2DL4, perforin,
and CD70, and simultaneous knockdown of Dnmt1 and
Dnmt3a caused greater demethylation and overexpression of
these genes than Dnmt1 alone [8]. T cells express little
Dnmt3b, so this isoform was not studied [12].
The present studies extend this work by demonstrating that
decreased ERK and JNK signaling contributes to demethyl-
ation of promoter sequences in CD4CD28– T cells by de-
creasing Dnmt levels. Dnmt1 is up-regulated by signals trans-
mitted through the ERK and JNK pathways [11]. Dnmt3a is
similarly up-regulated, in part, by signaling through the ERK
pathway [12], but the observation that JNK signaling regulates
Dnmt3a is novel.
T cell signaling abnormalities develop with age [27]. How-
ever, subset specificity has not been studied, and this is the
first report demonstrating ERK and JNK signaling abnormali-
ties in CD4CD28– cells. Functional consequences were con-
firmed by demonstrating that ERK and JNK inhibition or
knockdown in CD4 T cells replicated the Dnmt1 and
Dnmt3a decreases observed in the CD4CD28– subset [8]
and caused demethylation and overexpression of the TNFSF7
(CD70) gene. This indicates that the signaling defects contrib-
ute to overexpression of some genes in CD4CD28– cells
through effects on DNA methylation and consequently, chro-
matin structure. Notably, the same signaling abnormalities
were seen in CD4CD28– T cells from RA patients, the el-
derly, and T cells subjected to replicative senescence, indicat-
ing similar mechanisms in all three conditions.
The decrease in JNK activation is not a result of loss of
CD28, as CD28 is not required for JNK activation in T cells
[28]. Rather, the present studies demonstrate that CD4
CD28– T cells express PP5, which is a phosphatase that inhib-
its the JNK signaling pathway through effects on ASK1 [21,
22], and may contribute to the JNK pathway impairment in
CD28– T cells. PP5 also inhibits the ERK signaling pathway
through effects on Raf-1 [23]. PP5 is a regulator of stress-in-
duced signaling networks [29], including oxidative stress [21],
and its overexpression in the CD28– subset may similarly re-
flect a response to oxidative stress in these cells.
Others [2] have reported that the CD28– subset can be sub-
divided further based on markers such as CD27 and CD57.
Although these subsubsets were not addressed specifically in
the present studies, the fact that statistically significant differ-
ences were seen between the CD4CD28 and CD4CD28–
subsets, together with the flow cytometric studies showing sig-
naling abnormalities in a majority of the CD4CD28– T cells,
suggests that a majority of the cells within the CD4CD28–
subset is affected.
In summary, our previous work demonstrated that mainte-
nance Dnmt levels are decreased in CD4CD28– T cells, re-
sulting in demethylation and overexpression of genes that con-
tribute to some of the autoreactive, inflammatory, and cyto-
toxic abnormalities characterizing this subset [8]. The present
studies extend this work by demonstrating that impaired sig-
naling through the ERK and JNK pathways plays an important
role in the methyltransferase decrease. These studies also indi-
cate that stress-induced PP5 expression may contribute to the
signaling decreases. Further studies are now needed to define
the role of PP5 in the generation of the CD4CD28– subset
and whether development of these cells can be prevented with
inhibitors of oxidative stress. These studies are under way.
Figure 7. PP5 expression in cul-
tured, senescent CD4CD28– cells
from normal donors and in
CD4CD28 and CD4CD28– T
cells from RA patients and healthy
controls. (A) CD4CD28 and
CD4CD28– T cells were gener-
ated by repeated stimulation of
CD4 T cells from four healthy
controls (C1–C4) and then sepa-
rated into CD28 and CD28– sub-
sets using magnetic beads. The cells were then lysed and PP5 levels measured by immunoblotting using -actin as a control. (B) Densito-
metric analysis of PP5 relative to -actin in similar immunoblots performed on chronically restimulated CD4CD28 and CD4CD28–
T cells from eight donors (meansem). (C) Representative flow cytometric histograms gating on PP5 levels in CD4CD28 and
CD4CD28– T cells from a healthy control. The dark lines represent anti-PP5 and the shaded portion, isotype control. (D) Similar anal-
ysis of PP5 in CD4CD28– T cells from the same subject. PP5 MFI in CD4CD28– (solid bars) and CD4CD28 (open bars) T cells
from five healthy subjects age 60, four healthy subjects 60, and six RA patients. Results represent the mean  sem.
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